A Phase 1b, Randomized, Blinded, Placebo-Controlled Dose-Escalation Study of the Safety and Biological Activity of GS-9620 in HIV-1 Infected, Virologically Suppressed Adults

Trial Profile

A Phase 1b, Randomized, Blinded, Placebo-Controlled Dose-Escalation Study of the Safety and Biological Activity of GS-9620 in HIV-1 Infected, Virologically Suppressed Adults

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs Vesatolimod (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 28 Jun 2017 Status changed from recruiting to active, no longer recruiting.
    • 17 Apr 2017 Planned End Date changed from 1 Sep 2017 to 1 Nov 2017.
    • 17 Apr 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top